semaglutide covered by medi-cal 🚨 California Alert: Coverage for Obesity Medications at Risk Just two years after began covering FDA-approved GLP-1 medications for obesity, that coverage is set to end in January 2026 — a Ozempic will no longer be

You don't have to dive into the deep end right away

Despite this potential, given the known long-term benefit of lowering hemoglobin A1c in preventing DR progression, there does not appear to be any contraindication to initiating GLP-1/GIP agonist therapy with appropriate ocular monitoring

While formal evidence remains in development, the mechanistic rationale is compelling: sustained, gentle GLP-1 receptor activation may favorably influence glucose metabolism, cardiovascular integrity, and neuroprotection, all while maintaining tolerability and adherence

Immunomodulation: It helps regulate immune responses, promoting a balance between pro-inflammatory and anti-inflammatory signals